Загрузка...
Side Effects of Bone-Targeted Therapies in Advanced Breast Cancer
In up to 75% of cases, advanced breast cancer patients eventually develop bone metastases with often debilitating skeletal-related events (SREs). Osteoclast inhibitors are commonly used as therapeutic mainstay with clinical studies showing superiority of denosumab over bisphosphonates (e.g., zoledro...
Сохранить в:
| Опубликовано в: : | Breast Care (Basel) |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
S. Karger GmbH
2014
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4322699/ https://ncbi.nlm.nih.gov/pubmed/25759613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000368844 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|